Progression of sleep disturbances in Parkinson’s disease: a 5-year longitudinal study

Zheyu Xu1,2 · Kirstie N. Anderson2 · Seyed Ehsan Saffari3 · Rachael A. Lawson2 · K. Ray Chaudhuri4,5 · David Brooks2,6 · Nicola Pavese2,6,7

Received: 23 June 2020 / Revised: 31 July 2020 / Accepted: 4 August 2020 / Published online: 17 August 2020 © The Author(s) 2020

Abstract

Background  Sleep disorders can occur in early Parkinson’s disease (PD). However, the relationship between different sleep disturbances and their longitudinal evolution has not been fully explored.

Objective  To describe the frequency, coexistence, and longitudinal change in excessive daytime sleepiness (EDS), insomnia, and probable REM sleep behavior disorder (pRBD) in early PD.

Methods  Data were obtained from the Parkinson’s Progression Markers Initiative (PPMI). EDS, insomnia, and pRBD were defined using the Epworth Sleepiness Scale, MDS-UPDRS Part I sub-item 1.7, and RBD screening questionnaire.

Results  218 PD subjects and 102 controls completed 5 years of follow-up. At baseline, 69 (31.7%) PD subjects reported one type of sleep disturbance, 25 (11.5%) reported two types of sleep disturbances, and three (1.4%) reported all three types of sleep disturbances. At 5 years, the number of PD subjects reporting one, two, and three types of sleep disturbances was 85 (39.0%), 51 (23.4%), and 16 (7.3%), respectively. Only 41 (18.8%) patients were taking sleep medications. The largest increase in frequency was seen in insomnia (44.5%), followed by EDS (32.1%) and pRBD (31.2%). Insomnia was the most common sleep problem at any time over the 5-year follow-up. The frequency of sleep disturbances in HCs remained stable.

Conclusions  There is a progressive increase in the frequency of sleep disturbances in PD, with the number of subjects reporting multiple sleep disturbances increasing over time. Relatively a few patients reported multiple sleep disturbances, suggesting that they can have different pathogenesis. A large number of patients were not treated for their sleep disturbances.

Keywords  Parkinson’s disease · Sleep · Insomnia · RBD · EDS · PPMI

Introduction

Sleep disturbances are common in Parkinson’s Disease (PD) and are recognized to be present in the early stages of disease [1]. A broad range of sleep disorders are seen [1] with potential interactions existing between the different disorders. However, the relationship between these sleep...
disturbances remains to be fully investigated, as they have mostly been studied in isolation, in the context of a broad range of non-motor symptoms, in cross-sectional or in short-longitudinal cohorts.

Previously, a cross-sectional study by Suzuki and colleagues had investigated excessive daytime sleepiness (EDS), probable REM sleep behavior disorder (pRBD), and other PD-related sleep problems defined using the PD sleep scale (PDSS-2) in a cross-sectional cohort of PD patients in advanced disease. In that cohort, 20% of patients reported two types of sleep disturbances and 12.5% reported all three types of sleep disturbances, with significant overlap identified in the three sleep-related symptoms [2]. However, the PDSS-2 questionnaire itself has components with overlap with the reporting of EDS and pRBD, and does not allow the complaints of insomnia to be studied separately. Furthermore, it is unknown whether overlap observed between these commonly reported sleep-related symptoms in advanced disease is also observed in early PD.

The aim of this study was to examine the frequency, coexistence, and longitudinal changes over a 5-year period of the commonly reported sleep disturbances of EDS, insomnia, and pRBD in a large cohort of initially drug-naïve PD subjects. EDS, insomnia, and pRBD were defined using validated questionnaires to capture the patients’ subjective sleep complaints as reported in clinical settings. Findings were compared with healthy controls (HCs). The long duration of follow-up will help better understand the emergence and the relationship of the various sleep disturbances in early PD.

Methods

Study population

PD subjects and the HCs were identified from the Parkinson’s Progression Markers (PPMI) Initiative database. The PPMI is an ongoing longitudinal, multicentre observational clinical study of early PD patients with a clinical disease duration of less than 2 years who were initially treatment naïve. The diagnosis of PD had to be supported by in vivo evidence of nigrostriatal dopaminergic dysfunction by DAT SPECT. Control subjects recruited into the study had to be 30 years or older and not to have a first degree relative diagnosed with PD. The full list of inclusion and exclusion criteria can be found at the PPMI website (https://www.ppmi-info.org/). Each study site obtained local ethical approval.

For our analysis, we identified PD subjects in the PPMI database who had completed 5 years of follow-up. For these subjects, we downloaded baseline assessments and annual follow-up visits. When follow-up evaluations were unavailable, results were obtained from evaluations performed in the preceding or successive 6-month period. Since most patients started anti-parkinsonian medications between baseline and 2 years, we decided to perform the first follow-up evaluation relative to 2 years.

We also extracted data from HCs recruited in the PPMI study with 5-year follow-up. The RBD Screening Questionnaire (RBDSQ) was one of the battery of tests performed to characterize both PD subjects and HCs after inclusion into the PPMI study. As the presence of REM sleep behavior disorder (RBD) is now known to be strongly associated with future neurodegeneration, HCs who screened positive for RBD at any time point during this 5-year period were excluded from further analyses in our study.

Data were downloaded on 2nd November 2017.

Demographics and assessments:

The sleep disturbances evaluated include EDS, insomnia, and RBD. EDS was evaluated using the Epworth Sleepiness Scale [3] where subjects self-report their likelihood of falling asleep in the preceding month with scores of ≥ 10 indicating EDS [4].

Insomnia complaints were evaluated using sub-item 1.7 of the Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) [5]. Participants were asked: “Over the past week, have you had trouble going to sleep at night or staying asleep throughout the night? Consider how rested you felt after waking up in the morning.” Clinically relevant insomnia was defined as a MDS-UPDRS sub-item 1.7 score ≥ 2, which was previously used [6] and shown to have good correlation with other insomnia rating scales [7]. The presence of RBD was assessed using the RBDSQ [8]. Subjects were classified as positive for RBD if they scored > 5 [9]. However, since RBD was not confirmed by polysomnography, we have used the term probable RBD (pRBD) in this study.

Demographic and clinical data including PD medication and sleep-related medication use were obtained from the medication logs. The total daily Levodopa equivalent daily dose (LEDD) was calculated using the established methods [10]. Clinical motor assessments performed included the Hoehn and Yahr (H&Y) stage [11] and the MDS-UPDRS Part III [5]. Cognition was evaluated using the Montreal Cognitive Assessment (MOCA) [12].

Statistical analysis was performed using SPSS Version 24 for Windows (Armonk, NY:IBM Corp). Baseline demographics and clinical characteristics were compared between PD and HC groups using Chi-square or Fisher’s exact test for categorical variables and two-sample test and Mann–Whitney U test for continuous variables. Similar statistical tests were conducted to compare PD subjects with no sleep disturbance and at least one sleep disturbance.
The number of PD patients reporting multiple types of sleep disturbances (two and three) increased over 5 years. We selected data at the 5-year mark to investigate the association between demographics and clinical features (including age, LEDD, medication class of levodopa replacement therapy used, and MDS-UPDRS Part III scores) and number of reported sleep disturbances (none, one, two, or three) using Chi-Square or Fisher’s exact test and analysis of variance and Kruskal–Wallis test for categorical and continuous variables, respectively. Post hoc pairwise comparisons (versus “No reported sleep disturbance” group as reference) were made using two-sided two-sample t test and Mann–Whitney test for continuous variables and Chi-square or Fisher’s exact test for categorical variables. Similarly, the association between demographics and clinical variables PD subjects with no reported sleep disturbances, insomnia only, pRBD only, and EDS only at 5 years were also explored using the above-mentioned statistical methods. Bonferroni adjustment was used to correct for multiple testing. Statistical significance level was set at <0.05.

Results

Analysis of PPMI database and subject characteristics:

Baseline clinical assessments were available for 423 PD subjects. Out of which, 218 completed both baseline and 5-year follow-up and were included in the analysis, although some had missing data for intermediate assessments. Therefore, we had 202 subjects who completed evaluations for 2-year follow-up, 211 for 3-year follow-up, and 210 for 4-year follow-up. The clinical characteristics of these patients, except for disease duration, were not statistically different from those of the 205 patients excluded for the lack of 5-year follow-up (Supplementary Table 1).

Out of 196 HCs with available baseline clinical assessments, 127 had completed evaluations at 5 years. Of those, 25 HCs were excluded as their RBDSQ scores would suggest the presence of pRBD. In total, 102 HCs were included: 100 had evaluations for 2-year follow-up and 98 had evaluations for 3-year and 4-year follow-ups.

Except gender distribution (PD group had a higher proportion of male subjects compared to the HC group: 69% vs 57%, p = 0.05), PD subjects and HCs were comparable in terms of baseline demographic variables and use of sleep-related medications. The mean LEDD was 282 ± 233 mg, 397 ± 294 mg, 498 ± 289 mg, and 585 ± 336 mg at the 2-, 3-, 4-, and 5-year time points, respectively (Table 1).

At baseline, 16 (7.3%) PD subjects were using medications for sleep which increased to 41 (18.8%) PD subjects after 5 years (full details in Supplementary Table 2). In contrast, nine (8.9%) HCs were using medications for sleep at baseline which increased to 12 (11.8%) after 5 years.

Frequency of individual sleep disturbances over the 5-year period

Insomnia was the most common sleep problem reported by our PD patients at any assessment over the 5-year follow-up, followed by pRBD, and EDS. The comparison between PD patients and HCs showed that the proportion of PD and HCs reporting insomnia was not statistically different at baseline and 2-year time points. However, significantly more PD subjects reported insomnia compared to controls at years 3, 4, and 5 (Table 2). Similarly, the proportion of PD and HCs reporting EDS was not statistically different at baseline (p = 0.06), but a significantly higher proportion of PD subjects (compared to HCs) reported EDS at all other time points (p < 0.05) (Table 2).

Changes in the frequency of individual sleep disturbances over the 5-year period

In PD patients, the largest increase in frequency over 5 years was seen with insomnia, followed by EDS and then pRBD (Table 2).

At baseline, 45 (20.6%) PD subjects reported insomnia which increased to 97 (44.5%) at 5 years (p < 0.001). At baseline, 37 (17.0%) PD subjects reported pRBD which increased to 70 (32.1%) at 5 years (p < 0.001). At baseline, 46 (21.1%) PD subjects reported pRBD, which increased to 68 (31.2%) at 5 years (p = 0.005). In HCs, insomnia and EDS did not change significantly over time (Table 2). At baseline, 15 (14.7%) HCs reported insomnia which increased to 18 (17.7%) at 5 years (p = 0.405). At baseline, nine (8.8%) HCs reported EDS which increased to ten (9.8%) after 5 years (p = 0.763) (Table 2).

Coexistence of sleep disturbances in individual subjects

The percentage of PD subjects reporting multiple sleep disturbances increased over time, but this was not the case in the HCs (Fig. 1).

PD subjects

At baseline, 121 (55.5%) PD patients did not report any sleep disturbances. Sixty-nine (31.7%) PD patients reported one type of sleep disturbance: 28 (12.8%) reported insomnia only, 23 (10.6%) reported pRBD only, and 18 (8.3%) EDS only. Twenty-five (11.5%) PD patients reported two types of sleep disturbances: 11 (5.0%) reported both EDS and pRBD, nine (4.1%) reported both insomnia and pRBD, and
five (2.3%) reported both insomnia and EDS. Three (1.4%) PD patients reported all three types of sleep disturbances (Fig. 2a).

At 5 years, 66 (30.3%) PD patients did not report any sleep disturbances. Eighty-five (39.0%) PD patients reported one sleep type of disturbance: 42 (19%) reported insomnia only, 24 (11.0%) reported pRBD only, and 19 (8.7%) reported EDS only. Fifty-one (23.4%) PD patients reported two types of sleep disturbances; 23 (10.6%) reported both insomnia and EDS; 16 (7.3%) reported both insomnia and pRBD; and 12 (5.5%) reported both pRBD and EDS. Sixteen (7.3%) PD patients reported all three types of sleep disturbances (Fig. 2b).

**Healthy controls**

At baseline, 20 (19.6%) HCs reported one type of sleep disturbance, 13 (12.8%) insomnia, and 7 (6.9%) EDS. Two (2%) HCs reported two types of sleep disturbances (EDS and insomnia). At 5 years, 24 (23.5%) reported one type of sleep

---

**Table 1** Baseline clinical and demographic features of Parkinson’s disease (PD) and healthy controls (HCs)

|                              | Baseline information of PD subjects n = 218 | Baseline information of HCs n = 102 | p value |
|------------------------------|--------------------------------------------|-------------------------------------|---------|
| N (male/female) %            | (150/68) (68.8/31.2)                      | (58/44) (56.9/43.1)                | 0.050a  |
| Age (years)                  | 60.9 ± 9.4 (min 33, max 84)               | 59.2 ± 11.1 (min 31, max 81)       | 0.268b  |
| Disease duration (years)     | 0.59 ± 0.57 NA                            | NA                                  |         |
| Body mass index              | 27.1 ± 4.5 (min 18.7, max 43.8)           | 26.0 ± 4.3 (min 17.5, max 42.3)     | 0.528b  |
| MOCA                         | 27.1 ± 2.3                                 | 28.1 ± 1.0                         | 0.001b  |
| H & Y staging:               |                                            |                                     | <0.01a  |
| Stage 1                      | 105 (48.1%)                               | 1 (1.0%)                           |         |
| Stage 2                      | 111 (50.9%)                               | 0 (0.0%)                           |         |
| Stage 3                      | 2 (0.9%)                                  | 0 (0.0%)                           |         |
| MDS-UPDRS                    |                                            |                                     |         |
| Part I                       | 5.35 ± 3.84                               | 2.75 ± 2.98                        | <0.001b |
| Part II                      | 5.69 ± 4.19                               | 0.30 ± 0.79                        | <0.001b |
| Part III                     | 20.9 ± 8.3                                | 1.23 ± 2.17                        | <0.001b |
| Use of sleep-related medications n (%)| 16 (7.3%)                               | 9(8.9%)                            | 0.812a  |

Figures are mean ± SD unless otherwise indicated

H and Y Staging Hoehn and Yahr Staging, MDS-UPDRS Movement Disorders Society–Unified Parkinson’s Disease Rating Scale, NA not applicable, PIGD Postural Instability and Gait Disorder

aChi-square test

bMann–Whitney U test figure

---

**Table 2** Number and percentage of Parkinson’s disease (PD) and healthy controls (HCs) reporting the presence of insomnia and excessive daytime sleepiness across a 5-year period with between-group comparisons made between the PD and HCs

| Time point | Presence of insomnia symptoms | Presence of excessive daytime sleepiness | Presence of REM sleep behavior disorder |
|------------|--------------------------------|------------------------------------------|----------------------------------------|
|            | PD HCs p value*                | PD HCs p value*                          | PD HCs                                  |
| Baseline   | 45 (20.6) 15 (14.7) 0.223      | 37 (17) 9 (8.8) 0.060                    | 46 (21.1) NA                            |
| 2 years    | 64 (31.5) 21 (21) 0.058        | 47 (23.3) 11 (11) 0.013                  | 59 (29.1) NA                            |
| 3 years    | 73 (34.4) 20 (20.6) 0.016      | 59 (27.8) 11 (11.2) 0.001                | 68 (32.2) NA                            |
| 4 years    | 90 (42.7) 17 (17.4) 0.001      | 60 (28.6) 13 (13.3) 0.004                | 67 (31.9) NA                            |
| 5 years    | 97 (44.5) 18 (17.7) 0.001      | 70 (32.1) 10 (9.8) 0.001                 | 68 (31.2) NA                            |

NA not applicable

*a Chi-square test. Significant differences highlighted in bold

---
disturbance, 16 (15.7%) insomnia, and 8 (7.8%) EDS, and two (2.0%) HCs reported two types of sleep disturbances. Comparisons among PD subjects with and without sleep disturbances at 5 years

PD subjects were initially divided in two groups based on the absence or presence of sleep disturbance (insomnia or EDS or pRBD or any combination of the three sleep complaints) at 5 years. Statistically significant differences in LEDD at the 5-year follow-up were found between the two groups with higher median LEDD reported in subjects reporting sleep disturbances compared to subjects who reported no sleep disturbances [600 (400–800) vs. 455 (300–650) mg, \( p = 0.009 \)].

The two groups were not statistically different in patient age (\( p = 0.655 \)), gender (\( p = 0.443 \)), MOCA (\( p = 0.500 \)), MDS-UPDRS Part III scores (\( p = 0.456 \)), medication status (no medications, dopamine agonists only, levodopa only, and both dopamine agonists and levodopa) (\( p = 0.114 \)) and H & Y stage (\( p = 0.331 \)) (Supplementary Table 3).

Pairwise group comparisons were then made between PD subjects who reported no sleep disturbances and PD subjects who reported insomnia only, EDS only, and pRBD only. PD subjects who reported pRBD were more likely to be male compared to PD subjects who reported no sleep disturbances (87.5% versus 65.1%, \( p = 0.04 \)). PD subjects who reported
insomnia had a higher LEDD compared to PD subject who reported no sleep disturbances (639.7 ± 353.5 mg versus 495.2 ± 284.4 mg, \( p = 0.033 \)). All other group-wise comparisons including age, gender, BMI, MOCA, H & Y stage, MDS-UPDRS Part III scores, medication status, and LEDD were not statistically significant (Supplementary Table 4).

Finally, PD patients were grouped into whether they reported none, one, two, or three types of sleep disturbances at 5 years. Statistically significant differences in LEDD at the 5-year follow-up were found between groups using the Kruskal–Wallis test (\( \chi^2 = 11.54, p = 0.009 \)). Post hoc analysis found that subjects reporting three types of sleep disturbances had a higher median LEDD (800 mg) compared to subjects who reported no sleep disturbances (455 mg) (\( p = 0.006 \)). Subjects reporting only one sleep disturbance with a median LEDD of 512.5 mg and subjects reporting two sleep disturbances only with a median LEDD of 600 mg were not statistically different from subjects with no sleep disturbances. No other statistically significant differences were found.

The four groups were not significantly different in patient age \( (p = 0.413) \), gender \( (p = 0.510) \), MOCA \( (p = 0.289) \), and MDS-UPDRS Part III scores \( (p = 0.548) \). No group differences in medication status (no medications, dopamine agonists only, levodopa only, and both dopamine agonists and levodopa) were found between the patient groups using the Chi-square test \( (p = 0.562) \).

**Discussion**

Our study evaluated the longitudinal progression of three common sleep disturbances (EDS, insomnia, and RBD) and their interactions over a 5-year period in early PD. We found a progressive increase in the frequency of the different types of sleep disturbances. The greatest increase in frequency was observed for insomnia, followed by EDS and pRBD. Insomnia was also the most common sleep problem reported at any time over the 5-year follow-up. The percentage of patients with at least one type of sleep disturbance increased from 46% at baseline to 70% after 5 years. The percentage of patients with multiple sleep disturbances also increased over time, but remained relatively small. Interestingly, one-third of PD patients continued to remain free of sleep disturbances when assessed using our methodology. In contrast, we found that the frequency of sleep disturbances (EDS and insomnia) in HCs remained stable over time.

The novel aspect of our study is that we have assessed the coexistence of EDS, pRBD, and insomnia and their progression in individual patients over 5 years. In our longitudinal assessment, we found a progressive increase in the number of patients reporting multiple sleep disturbances. However, the proportion of these patients remained small. The low percentage of patients with multiple sleep problems suggests that the pathophysiology of the different sleep disturbances in early PD might be due to different mechanisms that attenuate or influence the co-expression of other sleep disturbances.

EDS in PD patients is multifactorial, but could potentially be caused by insomnia and poor sleep. However, in our cohort, only a minority of PD subjects had co-existing insomnia and EDS at baseline, with the proportion of patients with these two disturbances increasing over time but remaining low at 11%. Similarly, only 2% of HCs reported co-existing insomnia and EDS at baseline, which remained unchanged after 5 years. These findings would suggest that insomnia and EDS are not related in the majority of PD patients. We recently reported that EDS was associated with reduced postsynaptic dopaminergic receptor availability measured with \([11C]\)-PHNO PET, but that was not the case for sleep-onset and sleep-maintenance insomnia \([13]\).

However, we acknowledge that EDS could potentially be due to another undiagnosed primary sleep disorder such as obstructive sleep apnoea and Restless Legs syndrome, which were not assessed in this study. Similarly, the presence of comorbid mental health problems is likely to be relevant in an unknown proportion of patients with sleep-related complaints.

It is notable that one-third of our patients continued to remain free of sleep complaints. Although the use of questionnaires might have under-estimated the occurrence of sleep disorders, cross-sectional studies using polysomnography have also identified a proportion of patients (3.5–20%) free of sleep disturbances \([14–16]\), possibly representing a milder disease phenotype. PD subjects with no reported sleep complaints after 5 years did not differ from PD subjects who reported any sleep disturbance, except that higher LEDDs were observed in subjects who reported any sleep disturbance or insomnia only.

We have also evaluated the longitudinal progression of the individual sleep disturbances over the 5-year period. Only a few studies have examined the longitudinal change of different sleep disturbances in early PD often with inconsistent findings. One study performed over 2 years did not find any change in the reported frequencies of daytime somnolence, insomnia, and dream enactment in a cohort of 97 newly diagnosed PD patients \([17]\). However, no control population was investigated and the coexistence of different sleep problems in individual patients was not assessed. The same cohort of patients was reassessed at 4-year follow-up and, while there was a significant increase in frequency of EDS, the frequencies of insomnia and dream enactment were similar to baseline \([18]\). In another study, which used a self-designed sleep questionnaire, occurrence of insomnia in general remained stable from baseline through a 5-year period \([17–19]\). Using the
PPMI database over a shorter duration, Simuni and colleagues did not find any significant increase in reported frequency of EDS, insomnia, and pRBD over 2 years [20], while Amara and colleagues reported an increased frequency of EDS and pRBD over 3 years, but did not study insomnia [21]. Finally, two studies reported an increase in the frequency of pRBD in early PD cohorts [22, 23].

We found that insomnia was the most common sleep problem reported at any time over the 5-year follow-up. This finding is consistent with cross-sectional studies in advanced PD that also found insomnia to be the most commonly reported sleep disturbance [14, 24, 25]. However, we found that the frequency of insomnia in PD patients was significantly higher than in HCs only after 3 years of follow-up. Insomnia also had the greatest increase in frequency that rose steadily during the 5 years. This is consistent with polysomnographic studies showing progressive sleep destructuring with disease progression [26]. Taken together, these results would suggest that development of insomnia in PD mainly occurs in mid- to advanced stages of disease. However, our study design did not allow us to make the distinction between sleep-onset and sleep-maintenance insomnia. A previous study in early PD has suggested that the prevalence of sleep-maintenance insomnia increases over time, but that of onset insomnia decreases over time [19].

We also found that pRBD frequency increased from 21% at baseline to 31% after 5 years, which is consistent with findings from two previous studies in smaller cohorts of early PD patients [22, 23]. However, in comparison to these studies [22, 23], we report a slower increase in pRBD frequency of approximately 2% per year. This is probably due to the increasing proportion of subjects treated for RBD in our study over time.

We then assessed the possible effects of dopamine replacement drugs on sleep disorders. Our findings suggest that the overall impact of LEDD on the total number of reported sleep disorders was small. PD patients reporting three types of sleep disturbances had a higher median LEDD compared to subjects without sleep disturbances. However, no differences were observed in the other pairwise comparisons where subjects reported fewer (zero, one, or two) types of sleep disturbances, although there was a trend for higher LEDDs to be associated with increasing number of reported sleep disturbances. This observed trend could reflect more severe disease being associated with a greater number of sleep disturbances. However, this is also complicated by the use of dopamine agonists in younger patients in milder disease, which is associated with excessive somnolence. In other studies investigating isolated sleep symptoms in early PD, LEDDs have been reported to be higher in EDS [19] but not different in insomnia [19] and RBD [23].

The previous studies in early PD have not reported differences in MDS-UPDRS Part III scores in subjects reporting EDS [27, 28], insomnia [19], and RBD [23, 29]. Consistent with the previous studies, we did not find differences in age and number of sleep disturbances [21, 27, 28], insomnia [19], and RBD [23, 29].

Interestingly, despite finding a progressive increase in the frequency of the different types of sleep disturbances in our patients and, at the 5-year visit, 70% of the patients were complaining of sleep problems, there was only a small increase in the proportion of patients taking sleep medications at 5-year follow-up compared to baseline. Although it is possible that not all sleep complaints are severe enough to require medical therapy, our findings indicate that a large number of patients with PD do not receive the appropriate clinical attention for their sleep disorder.

The major strength of the study is the large number of well-characterized early PD subjects who were assessed at multiple time points. Additionally, the high retention rate allowed for the longitudinal analysis of sleep characteristics. Thus, our findings are based on assessments that can be performed as part of the routine standard of care and realistically reflect the patients’ subjective sleep complaints reported in clinical settings. There are, however, a number of limitations. While the MDS-UPDRS sub-item 1.7 was previously used [6] to screen clinically relevant insomnia and shown to have good correlation with other insomnia rating scales [7], we did not perform any objective measures of EDS or RBD. Therefore, the real frequency of sleep symptoms and other undiagnosed primary sleep disorders in our patients could be under-estimated in the absence of polysomnography. However, we wanted to capture the prevalence of sleep problems with simple tools that could reflect the complaints reported by the patients and be used in routine clinical settings. There was a higher proportion of male subjects in the PD group relative to the HCs group, which could have either over-estimated or under-estimated the relative expression of the different sleep disturbances. In the general population, the male gender was associated with a lower reporting of insomnia complaints [30, 31] but higher reporting of dream enactment behaviors [32]. In the PD population, gender has been shown not to influence reporting of RBD using the RBDSQ [33], but more frequent reporting of EDS [27, 34, 35]. Overall, the effect of gender on sleep complaints could have under-estimated the frequency of increased insomnia complaints in the PD group relative to the HC group, but over-estimated the relative increased frequency of EDS and RBD in our cohort.

In conclusion, we present 5-year longitudinal data from the PPMI cohort and show that the frequency of insomnia, EDS, and pRBD all increase over time in early PD, with insomnia frequency increasing most rapidly. At the individual level, the profile of sleep disturbances reported was
variable, necessitating careful clinical assessment to identify the underlying sleep complaints, as they have different treatments. Although sleep disturbances are common, one-third of the PPMI cohort remained free of sleep complaints after 7 years of disease. Finally, the small number of patients with multiple types of sleep disturbances suggests that the different disturbances have different pathogenesis.

Acknowledgements The authors will like to thank all participants for their contribution towards this study.

Author contributions ZX: conception and design, statistical analysis, and writing of the manuscript. NP: conception and design, review, and critique of manuscript. SES: statistical analysis and critique of the manuscript. RAL: review and critique of statistical analysis, and review and critique of manuscript. RAL, KRC, and DB: review of statistical analysis, and review and critique of manuscript.

Funding RC reports grants from Britannia Pharmaceuticals, AbbVie, UCB, GKC, Bial, Academic grants: EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, and personal fees from Honoraria for lectures: AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim Neuroderm, Sunovion and also sits on the advisory board of AbbVie, UCB, Sunovion, Pfizer, Jazz Pharma, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion. FJB reports grants from The Independent Research Fund Denmark, Lundbeck Foundation, The Danish Parkinson Association, European Union FP7 program, and Alzheimer’s Research UK, and personal fees from GE Healthcare and Plexxikon. NP reports grants from The Independent Research Fund Denmark, Parkinson’s UK, the MSA Trust, and the Danish Parkinson’s disease Association. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability Source data are available on the PPMI website.

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflict of interest.

Ethical approval Ethical approval was obtained from the individual PPMI study sites.

Informed consent Informed consent was obtained from the individual PPMI study sites.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bargiotas P, Schuepbach MW, Bassetti CL (2016) Sleep-wake disturbances in the premotor and early stage of Parkinson’s disease. Curr Opin Neurol 29(6):763–772. https://doi.org/10.1097/WCO.0000000000000388

2. Suzuki K, Okuma Y, Uchiyama T, Miyamoto M, Sakakibara R, Shimo Y, Hattori N, Kuwabara S, Yamamoto T, Kaji Y, Hirano S, Kadowaki T, Hirata K, Ni K (2017) Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson’s disease: a multicentre cross-sectional study. J Neurol Neurosurg Psychiatry 88(11):953–959. https://doi.org/10.1136/jnnp-2017-316136

3. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14(6):540–545

4. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, Lacomblez L, Golmard JL, Derenne JP, Agid Y (2002) Parkinson’s disease and sleepiness: an integral part of PD. Neurology 58(7):1019–1024

5. Goetz CG, Tilley BC, Shafman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Movement Disorder Society URTF (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170. https://doi.org/10.1002/mds.22340

6. Rutten S, Vriend C, van der Werf YD, Berendse HW, Weintraub D, van den Heuvel OA (2017) The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naive Parkinson’s disease. Parkinsonism Relat Disord 39:31–36. https://doi.org/10.1016/j.parkreldis.2017.01.015

7. Gallagher DA, Goetz CG, Stebbins G, Lees AJ, Schrag A (2012) Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Mov Disord 27(1):79–83. https://doi.org/10.1002/mds.23939

8. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutbrunner M, Oertel WH (2007) The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord 22(16):2386–2393. https://doi.org/10.1002/mds.21740

9. Nomura T, Inoue Y, Kagimura T, Uemura Y, Nakashima K (2011) Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson’s disease patients. Sleep Med 12(7):711–713. https://doi.org/10.1016/j.sleep.2011.01.015

10. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653. https://doi.org/10.1002/mds.23429

11. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442

12. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

13. Pagano G, Molloy S, Bain PG, Rabiner EA, Chaudhuri KR, Brooks DJ, Pavese N (2016) Sleep problems and hypothalamic dopaminergic D3 receptor availability in Parkinson disease. Neurology 87(23):2451–2456. https://doi.org/10.1212/01.WNL.000000800000003396

14. Alatriste-Booth V, Rodriguez-Violante M, Camacho-Ordenez A, Cervantes-Arriaga A (2015) Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study. Arq
15. Norlinh MI, Afidah KN, Noradina AT, Shamsul AS, Hamidon BB, Sahatvehan R, Raymond AA (2009) Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS. Parkinsonism Relat Disord 15(9):670–674. https://doi.org/10.1016/j.parkreldis.2009.02.012

16. Sobreira-Neto MA, Pena-Pereira MA, Sobreira EST, Chagas MHN, Fernandes RMF, Tumas V, Eckeli AL (2017) High frequency of sleep disorders in Parkinson's disease and its relationship with quality of life. Eur Neurol 78(5–6):330–337. https://doi.org/10.1159/000481939

17. Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Longo K, Cozzolino A, Giordano F, De Rosa A, De Michele G, Pellecchia MT, Barone P (2013) Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84(1):14–17. https://doi.org/10.1136/jnnp-2012-303419

18. Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Santangelo G, Pellecchia MT, Barone P (2016) The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. Eur J Neurol 23(11):1673–1679. https://doi.org/10.1111/ejn.13106

19. Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD (2017) Changes in insomnia subtypes in early Parkinson disease. Neurology 88(4):352–358. https://doi.org/10.1212/WNL.0000000000005540

20. Simuni T, Caspell-Garcia C, Coffey CS, Chahine LM, Marek K (2018) Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. J Neurol Neuropsychiatry Psychiatry 89(1):78–88. https://doi.org/10.1136/jnnp-2017-316213

21. Amara AW, Chahine LM, Caspell-Garcia C, Long JD, Coffey C, Hogl B, Videnovic A, Iranzo A, Mayer G, Foldvary-Schaefer N, Postuma R, Oertel W, Lasch S, Marek K, Simuni T, Parkinson's Progression Markers I (2017) Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. J Neurol Neurosurg Psychiatry 88(8):653–662. https://doi.org/10.1136/jnnp-2016-315023

22. Bugallo P, Viana-Baptista M (2013) REM sleep behavior disorder and motor dysfunction in Parkinson's disease—a longitudinal study. Parkinsonism Relat Disord 19(12):1084–1087. https://doi.org/10.1016/j.parkreldis.2013.07.017

23. Sixel-Doring F, Zimmermann J, Wegener A, Mollenhauer B, Trenkwalder C (2016) The evolution of REM sleep behavior disorder in early Parkinson disease. Sleep 39(9):1737–1742. https://doi.org/10.5665/sleep.6102

24. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarrello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatraro R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD, Group Ps (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24(11):1641–1649. https://doi.org/10.1002/mds.22643

25. Kurtis MM, Rodriguez-Blazquez C, Martinez-Martin P, Group E (2013) Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 19(12):1152–1155. https://doi.org/10.1016/j.parkreldis.2013.07.026

26. Diederich NJ, Vaillant M, Mancuso G, Lyen P, Tiete J (2005) Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients. Sleep Med 6(4):313–318. https://doi.org/10.1016/j.sleep.2005.03.011

27. Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD (2015) Development of excessive daytime sleepiness in early Parkinson disease. Neurology 85(2):162–168. https://doi.org/10.1212/WNL.000000000001737

28. Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, Mayer G, Hogl B, Postuma R, Videnovic A, Amara AW, Marek K, Investigators PSWgobotP (2015) Correlates of excessive daytime sleepiness in de novo Parkinson's disease: a case control study. Mov Disord 30(10):1371–1381. https://doi.org/10.1002/mds.26248

29. Plomhause L, Dujardin K, Duhamel A, Dellaioa M, Derambure P, Defebvre L, Monaca Charley C (2013) Rapid eye movement sleep behavior disorder in treatment-naive Parkinson disease patients. Sleep Med 14(10):1035–1037. https://doi.org/10.1016/j.sleep.2013.04.018

30. Valipour A, Lothaler H, Rauscher H, Zwick H, Burghuber OC, Lavie P (2007) Gender-related differences in symptoms of patients with suspected breathing disorders in sleep: a clinical population study using the sleep disorders questionnaire. Sleep 30(3):312–319

31. Ratti PL, Negre-Pages L, Perez-Lloret S, Manni R, Damier P, Tison F, Destee A, Rascol O (2015) Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: insights from a cross-sectional evaluation of the French CoPark cohort. Parkinsonism Relat Disord 21(11):1323–1329. https://doi.org/10.1016/j.parkreldis.2015.09.025

32. Zhou J, Zhang J, Li Y, Du L, Li Z, Lei F, Wing YK, Kushida CA, Zhou D, Tang X (2015) Gender differences in REM sleep behavior disorder: a clinical and polysomnographic study in China. Sleep Med 16(3):414–418. https://doi.org/10.1016/j.sleep.2014.01.020

33. Poryazova R, Oberholzer M, Baumann CR, Bassetti CL (2013) REM sleep behavior disorder in Parkinson's disease: a questionnaire-based survey. J Clin Sleep Med 9(1):55–59A. https://doi.org/10.5664/jcsm.2340

34. Zhu K, van Hilten JJ, Marinus J (2016) Course and risk factors for excessive daytime sleepiness in Parkinson's disease. Parkinsonism Relat Disord 24:34–40. https://doi.org/10.1016/j.parkreldis.2016.01.020

35. Martinez-Martin P, Falup-Pecurariu C, Odin P, van Hilten JJ, Antonini A, Rojo-Abuin JM, Borges V, Trenkwalder C, Aarsland D, Brooks DJ, Ray KC (2012) Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. J Neurol 259(8):1639–1647. https://doi.org/10.1007/s00415-011-6392-3